A new tissue kallikrein-like protease, blarinasin, has been purified from the salivary glands of the short-tailed shrew Blarina brevicauda. Blarinasin is a 32-kDa N-glycosylated protease with isoelectric values ranging between 5.3 and 5.7, and an optimum pH of 8.5 for enzyme activity. The cloned blarinasin cDNA coded for a pre-pro-sequence and a mature peptide of 252 amino acids with a catalytic triad typical for serine proteases and 43.7-54.0% identity to other mammalian tissue kallikreins. Blarinasin preferentially hydrolysed Pro-Phe-Arg-4-methylcoumaryl-7-amide (MCA) and N-tert-butyloxycarbonyl-Val-LeuLys-MCA, and preferentially converted human highmolecular-weight kininogen (HK) to bradykinin. The activity of blarinasin was prominently inhibited by aprotinin (K i s3.4 nM). A similar kallikrein-like protease, the lethal venom blarina toxin, has previously been purified from the salivary glands of the shrew Blarina and shows 67.9% identity to blarinasin. However, blarinasin was not toxic in mice. Blarinasin is a very abundant kallikrein-like protease and represents 70-75% of kallikrein-like enzymes in the salivary gland of B. brevicauda.
The American short-tailed shrew Blarina brevicauda is one of the few venomous mammals in the world (Dufton, 1992) . This shrew produces a potent salivary venom that may cause paralysis and death due to respiratory failure and circulatory malfunctions in mouse-sized animals (Pearson, 1942; Pucek, 1968) . B. brevicauda eats insects and vertebrates, including some larger than itself, such as murid rodents and frogs (Babcock, 1914; Churchfield, 1990) . Hence, this shrew may use venom to catch its prey.
According to the fossil record, the Insectivora may be one of the longest established mammalian orders and is probably that from which other placental orders ultimately descended (Crompton et al., 1978; Crompton and Jenkins, 1979) . Thus, enzymes produced by insectivores are expected to be more primitive than their counterparts in higher mammals, and may provide important information concerning enzyme structure and function in mammals. Few serine proteases from the Insectivora have been identified. A 30-kDa tissue kallikrein from the salivary gland of the Eastern Atlantic mole Scalopus aquaticus has been partially purified (Richards et al., 1996) , and the genes of several serine proteases, such as factor X and neutrophil elastase, have been cloned from a spleen cDNA library of the platypus Ornithorhynchus anatinus (Poorafshar et al., 2000) .
Due to the interesting ecology of shrews, we sought to isolate biologically active substances from the shrew B. brevicauda. Recently, we purified and characterised the blarina toxin (BLTX), a lethal mammalian venom from the submaxillary and sublingual glands (Kita et al., 2004) . It consists of a mature peptide of 253 amino acids with a high degree of identity with tissue kallikrein. Mice administered BLTX developed irregular respiration, paralysis and convulsions before dying. BLTX converts kininogens to kinins and causes vasodilation, although the mechanisms underlying its lethal toxicity have not been characterised. In the course of BLTX purification, we found a new kallikrein-like protease named blarinasin from B. brevicauda salivary glands. We report here the purification, characterisation and molecular cloning of the gene encoding blarinasin and discuss its structure and enzymatic properties compared to those of BLTX.
Blarinasin was purified from extracts of B. brevicauda submaxillary and sublingual glands (salivary glands) through a series of standard chromatographic proce- (A) SDS/PAGE analysis of blarinasin under reducing conditions. Purified blarinasin (180 ng) was run on a 12.5% polyacrylamide gel, and protein bands were visualised by silver staining. (B) Analysis of the extracts of Blarina salivary glands by 2D-PAGE. Cysteine residues were carbamidomethylated with iodoacetamide. The protein bands were stained with SYPRO Ruby and analysed at excitation and emission wavelengths of 532 and 610 nm, respectively. Arrows 1-3 and 4-11 indicate the spots for BLTX and blarinasin, respectively.
dures. The BLTX fraction identified by toxicity was completely separated from blarinasin on a Mono-Q anion exchange column chromatography during the course of purification (Kita et al., 2004) . Enzyme activity was assessed by measuring the proteolysis of Pro-Phe-Arg-4-methyl-coumaryl-7-amide (MCA). Proteolytic activity coincided with a protein peak in analytical gel permeation, anion-exchange, and hydrophobic high-performance liquid chromatography. Starting from 17.1 mg of shrew salivary glands, 32.3 mg of purified blarinasin was obtained with a total recovery of 4.7% and a 5.58-fold purification from the crude extract. Blarinasin was unstable and lost its activity on gel permeation chromatography at room temperature, as well as on freezing and thawing. Purified blarinasin yielded a single protein band with a molecular mass of approximately 32 kDa under reducing conditions on SDS/PAGE ( Figure 1A) . A comparison of the 2D-PAGE pattern of the crude B. brevicauda salivary gland extract with purified blarinasin revealed that blarinasin migrated as eight major spots with similar molecular sizes and different isoelectric points between 5.3 and 5.7 (arrows 4-11, Figure 1B) . BLTX migrated as three spots (arrows 1-3) with higher isoelectric points than most of the blarinasin spots on 2D-PAGE. Based on the specific activity of blarinasin and the 2D-PAGE pattern of extracted salivary glands, blarinasin was estimated to be 70-75% of the total kallikrein activity found in salivary glands. By comparison, BLTX (Kita et al., 2004) accounts for approximately five-fold less activity than blarinasin. Blarinasin at up to 20 mg kg -1 i.p. was not toxic in mice, whereas the LD 50 of BLTX was approximately 1 mg kg -1 (data not shown). Blarinasin cDNA was cloned from B. brevicauda submaxillary and sublingual glands by PCR using degenerate oligonucleotides designed from the sequences of the N-terminus tryptic peptide fragments and the consensus sequences of active sites of serine proteases. The isolated cDNA consisted of 962 bp and contained a single putative open reading frame of 843 bp with a proposed initiation codon of ATG at nucleotide 42, and a 39-untranslated region of 78 bp with a polyadenylation signal (AATAAA) and a poly(A) tail. The deduced amino acid sequence of blarinasin, the N-terminal 15 residues of amino acid sequence starting from an I-V-G-G serine protease motif and the sequences of seven trypsin cleavage fragments (K1-K7), are shown in Figure 2 . Blarinasin was composed of 281 amino acids with a pre-prosequence and an active mature protein composed of 252 amino acids. The predicted molecular mass of blarinasin was 28.0 kDa. Due to the presence of one predicted Nglycosylation site (Asn 122 ), purified blarinasin was treated with N-and/or O-glycosidase under denaturing conditions. After treatment with N-glycosidase, the 32-kDa blarinasin protein band shifted to a single 27-28-kDa band on SDS/PAGE, consistent with the molecular mass of the mature polypeptide backbone of blarinasin calculated (data not shown).
The optimum pH for the enzyme activity of blarinasin was 8.5, identical to the value reported for tissue kallikreins (Mason et al., 1983; Fukushima et al., 1985) and nearly equal to that for BLTX (Kita et al., 2004) . Table 1 shows the substrate specificity of blarinasin and BLTX. Blarinasin preferentially hydrolysed substrates with an Arg or Lys at the P1 position and a hydrophobic amino acid at the P2 position. Of the substrates tested, BocVal-Leu-Lys-MCA was the best substrate, with specific activity of 6.82 U/mg protein. Boc-Glu-Lys-Lys-MCA, Boc-Glu(OBzl)-Ala-Arg-MCA, Boc-Val-Pro-Arg-MCA, ZPhe-Arg-MCA and Pro-Phe-Arg-MCA, which are synthetic substrates for plasmin, factor XIa, a-thrombin, plasma kallikrein, and tissue kallikrein, respectively, were the second-best substrates, although the activity with these substrates was 3-5% of that with Boc-Val-LeuLys-MCA. Substrates with hydrophobic amino acids, such as Tyr, Phe, Ala, and Pro, in the P1 position were also hydrolysed, but at only 0.1-1% of the activity for Boc-Val-Leu-Lys-MCA. On the other hand, BLTX showed a narrow substrate specificity and both Pro-Phe-Arg-MCA and Boc-Val-Leu-Lys-MCA were the best substrates, with specific activity of 267.4 and 244.1 mU/mg protein, respectively. Experimentally identified amino acid sequences of the N-terminal 15 residues of the purified blarinasin and the tryptic peptides (K1-K7) are underlined. The translation initiation site (ATG) and stop codon (TAA) are boxed. The putative N-glycosylation site in the blarinasin sequence is highlighted in black. Isolation of the total RNA from the submaxillary and sublingual glands of B. brevicauda, preparation of first-strand cDNA template, and RT-PCR using degenerate oligonucleotides designed from conserved amino acid sequences within the active sites of mammal kallikreins were carried out as described previously (Kita et al., 2004) . Of 22 independent clones sequenced, seven matched the sequences corresponding to the amino acid sequences within blarinasin. BLTX and one minor tissue kallikrein isoform were obtained from the other clones. Two cycles of 39-rapid amplification of cDNA ends (RACE) were carried out. The reaction mixture for the first cycle contained two primers, KLK-gene1 and Oligo-dT, and used the blarinasin cDNAs described above as templates. The reaction mixture for the second cycle contained the two primers KLK-gene2 and Oligo-dT and the PCR products of the first reaction. The nucleotide sequences of KLK-gene1 and KLK-gene2, the gene-specific primers for blarinasin, and Oligo-dT are 59-GGC AGC ATG AAT CCA TAC AGC-39, 59-ATG AGT GTT CCC GCT CCC AC-39, and 59-CGC AGG AAT TTT TTT TTT TTT TT-39, respectively. For the 59-RACE reaction, PCR was carried out using a universal primer mix (long, 59-CTA ATA CGA CTC ACT ATA GGG CAA GCA GTG GTA TCA ACG CAG AGT-39; short, 59-CTA ATA CGA CTC ACT ATA GGG C-39) and the gene-specific primer KLK-gene3, with the sequence 59-GAT CTC GTC GTA GTA GGT ATC GTT CA-39. The full-length blarinasin cDNA was confirmed by PCR using KLK-gene4 and KLK-gene5. The nucleotide sequences of KLK-gene4 and KLK-gene5 are 59-GCC ACC ATG TAC CTC CTG CTC CT-39 and 59-GCA TTT AGC TGT GTG TTG CGA T-39, respectively. The PCR conditions were as follows: initial denaturing at 948C for 3 min, followed by 30 cycles of 30 s of denaturing at 948C, 30 s of annealing at 608C, and 60 s of extension at 728C, and a final extension at 728C for 7 min. The amplified DNA fragments were subcloned and seven independent clones were sequenced. All clones revealed an identical sequence.
The activity of blarinasin was markedly inhibited by aprotinin at a concentration of 0.1 mM (K i s3.4=10 -9 M), moderately inhibited by secretory leukoprotease inhibitor (SLPI; K i s8.7=10 -8 M), leupeptin, benzamidine and phenylmethanesulfonyl fluoride (PMSF) at a concentration of 1 mM, and not inhibited by EDTA or a 1 -protease inhibitor (a 1 PI) ( Table 2 ). The inhibitor spectrum of blarinasin shows significant similarity to that of BLTX.
Blarinasin converted human HK into a major 58-63-kDa protein fragment and various smaller peptides in a time-dependent manner on SDS/PAGE analysis (data not shown). The major peptide generated after HK hydrolysis Enzyme activity using peptidyl-MCA substrates was analysed as previously described (Kido et al., 1992) . Reactions were initiated by adding enzyme samples to 0.1 mM substrate in 50 mM Tris/HCl buffer, pH 8.5, in a total volume of 0.5 ml. Relative activity is expressed as percentage of the activity toward ProPhe-Arg-MCA (blarinasin, 7.02 mU/ml; BLTX, 5.68 mU/ml). Boc, t-butoxycarbonyl; Z, benzyloxycarbonyl; Bz, benzoyl; Glt, glutaryl; Suc, succinyl. HK at a dose of 10 mg was incubated with 400 ng of blarinasin in 50 mM Tris-HCl, pH 8.5, at 378C for 1 h, as previously described (Kita et al., 2004) . (A) After incubation, products in the reaction mixture were separated by HPLC. The upper and lower traces show the peptides released from HK after incubation with blarinasin and standard kinins (50 ng each), respectively. The solid horizontal bar indicates BK. (B) Kinin concentrations in the reaction mixtures were determined with a competitive enzyme-linked immunosorbent assay (ELISA) using a Markit-M bradykinin kit (Dainippon Pharmaceutical Co Ltd, Osaka, Japan).
by blarinasin was bradykinin (BK) (Figure 3 ), similar to those generated by BLTX and porcine pancreas kallikrein (PPK). The amino acid sequence of mature blarinasin shows the highest identity of 67.9% with BLTX, and identity of 54.0, 54.0, 53.6, 54.0, 44.0, 43.7, 32.9 , and 30.0% with monkey glandular kallikrein from the crab-eating macaque Macaca fascicularis (Lin et al., 1993) , dog pancreas kallikrein from Canis familiaris (Gauthier et al., 1994) , human tissue kallikrein 1 (hK1) (Fukushima et al., 1985) , human prostate specific antigen (PSA) (Watt et al., 1986) , mouse tissue kallikrein 1 (mGK1) (Mason et al., 1983) , rat urinary kallikrein 1 (RUK1) (Swift et al., 1982) , Figure 4 Structure-based sequence alignment of active forms of blarinasin, BLTX, and several proteases of the tissue kallikrein family. Putative catalytic site residues are marked with a diamond (ࡗ). Arrows show putative processing sites in pro-and mature forms of blarinasin, BLTX, and various kallikreins. Amino acid sequences that are identical in )5 of the 10 sequences are highlighted in black. BLTX, blarina toxin; monkey kallikrein, glandular kallikrein 1 from the crab-eating macaque Macaca fascicularis; dog kallikrein, pancreas kallikrein from Canis familiaris; hK1, human tissue kallikrein 1; human PSA, human prostate-specific antigen (tissue kallikrein 3); mGK1, mouse tissue kallikrein 1; RUK1, rat urinary kallikrein 1; and huPK, human plasma kallikrein.
human plasmin (Malinowski et al., 1984) , and human plasma kallikrein (huPK) (Chung et al., 1986) , respectively (Figure 4 ). Blarinasin has highly conserved residues flanking the residues of the catalytic triad (His (Asp   138   ) are rare, and have only been shown in the sequences of gila toxin (GTX) and horridum toxin, venoms from the Mexican lizard Heloderma horridum (Utaisincharoen et al., 1993) . The pre-pro-sequence of blarinasin also showed high similarity to the mammalian tissue kallikreins listed in Figure 4 , except for a unique insertion of six residues, P 20 GPSIE
25
.
Blarinasin hydrolysed Boc-Val-Leu-Lys-MCA most rapidly, and its specific activity with this substrate was 27.9-fold higher than that of BLTX. On the other hand, BLTX preferentially hydrolysed Pro-Phe-Arg-MCA at a specific activity 1.37-fold higher than that of blarinasin. The former substrate for blarinasin and its analogues, such as D-and/or DL-Val-Leu-Lys-pNA, are known as general substrates for plasmin. The substrate specificity of blarinasin is similar to that of hK1 (Fujimoto et al., 1990) , PPK (Blaber et al., 1989) , and RUK1 (Bedi, 1992) . These observations suggest that lysine at the P1 site is favoured for blarinasin. As with BLTX, aprotinin and SLPI efficiently inhibited the activity of blarinasin. In contrast, UTI, benzamidine, and PMSF moderately inhibited the activity of blarinasin at concentrations of 1 mM, but these inhibitors inhibited the activity of BLTX slightly (Kita et al., 2004) . Despite the similarities between the amino acid sequences and the enzymatic properties of blarinasin and BLTX, blarinasin did not show any toxicity against mice, as observed with other mammalian tissue kallikreins.
In general, tissue kallikreins are acidic N-and O-glycoproteins with molecular heterogeneity. Both blarinasin and BLTX showed micro-heterogeneity for N-glycosylation. Analysis of blarinasin and BLTX by SDS/PAGE revealed bands of different molecular size (32 and 35 kDa), and after deglycosylation these bands were shifted to a single band with a molecular mass of 27-28 kDa. Based on the typical N-glycosylation motif (Asn-Xaa-Ser/Thr), blarinasin has a putative N-glycosylation site at Asn 122 (Figure 2 ), while BLTX possesses two. This difference in glycosylation may play a role in the different toxicity and enzymatic properties of blarinasin and BLTX.
Among lizard venoms, GTX and horridum toxin are classified as kallikrein analogues because of their amino acid sequences and protease activity (Hendon and Tu, 1981; Utaisincharoen et al., 1993; Datta and Tu, 1997) . The LD 50 value for injected GTX and horridum toxin is 2.5 mg kg -1 body weight i.v., but lethality may be synergistically increased approximately eight-fold when combined. In contrast, the toxicity of BLTX was not influenced by blarinasin. Although the in vivo substrates of these two kallikrein-like proteases have not been clarified, blarinasin may be a typical tissue kallikrein-like protease secreted in the B. brevicauda salivary glands, similar to other mammalian tissue kallikreins. On the other hand, BLTX cleaves substrates that result in products that cause paralysis and respiratory failure.
